# TPG RE Finance Trust, Inc.: financial statements, quarterly

TRTX · NYSE · CIK 1630472 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trtx.md) · [Financials](/companies/trtx/financials.md) · [Filings](/companies/trtx/filings.md) · [Insiders](/companies/trtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [62.8 d](/filings/0001630472-24-000006.md) | [55.4](/filings/0001630472-24-000012.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1 d](/filings/0001630472-26-000004.md) | [0.4](/filings/0001630472-25-000013.md) | [0.1](/filings/0001630472-25-000022.md) | [0.1](/filings/0001630472-25-000030.md) | [(0.2) d](/filings/0001630472-26-000004.md) | [0.1](/filings/0001630472-26-000017.md) | [0.1](/filings/0001630472-26-000026.md) | [0.1](/filings/0001630472-26-000030.md) | [0.1 d](/filings/0001630472-26-000004.md) | [0.1](/filings/0001630472-26-000017.md) | [0.1](/filings/0001630472-26-000026.md) | [0.1](/filings/0001630472-26-000030.md) |
| Net income | $m | [6.4 d](/filings/0001630472-26-000004.md) | [16.7](/filings/0001630472-25-000030.md) | [24.7](/filings/0001630472-25-000030.md) | [22.2](/filings/0001630472-25-000030.md) | [10.7 d](/filings/0001630472-26-000004.md) | [13.7](/filings/0001630472-26-000030.md) | [20.6](/filings/0001630472-26-000030.md) | [22.0](/filings/0001630472-26-000030.md) | [4.0 d](/filings/0001630472-26-000004.md) | [18.9](/filings/0001630472-26-000030.md) | [13.1](/filings/0001630472-26-000030.md) | [9.4](/filings/0001630472-26-000030.md) |
| Diluted EPS | $ per share | not reported | [0.17](/filings/0001630472-25-000013.md) | [0.26](/filings/0001630472-25-000022.md) | [0.23](/filings/0001630472-25-000030.md) | not reported | [0.12](/filings/0001630472-26-000017.md) | [0.21](/filings/0001630472-26-000026.md) | [0.23](/filings/0001630472-26-000030.md) | not reported | [0.19](/filings/0001630472-26-000017.md) | [0.12](/filings/0001630472-26-000026.md) | [0.08](/filings/0001630472-26-000030.md) |
| Basic EPS | $ per share | not reported | [0.17](/filings/0001630472-25-000013.md) | [0.26](/filings/0001630472-25-000022.md) | [0.23](/filings/0001630472-25-000030.md) | not reported | [0.12](/filings/0001630472-26-000017.md) | [0.21](/filings/0001630472-26-000026.md) | [0.23](/filings/0001630472-26-000030.md) | not reported | [0.19](/filings/0001630472-26-000017.md) | [0.12](/filings/0001630472-26-000026.md) | [0.08](/filings/0001630472-26-000030.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [206](/filings/0001630472-25-000005.md) | [203](/filings/0001630472-24-000012.md) | [259](/filings/0001630472-24-000025.md) | [226](/filings/0001630472-24-000028.md) | [190](/filings/0001630472-26-000004.md) | [363](/filings/0001630472-25-000013.md) | [166](/filings/0001630472-25-000022.md) | [93.6](/filings/0001630472-25-000030.md) | [87.6](/filings/0001630472-26-000030.md) | [92.0](/filings/0001630472-26-000017.md) | [65.6](/filings/0001630472-26-000026.md) | [70.8](/filings/0001630472-26-000030.md) |
| Total assets | $m | [4,214](/filings/0001630472-25-000005.md) | [3,829](/filings/0001630472-24-000012.md) | [3,696](/filings/0001630472-24-000025.md) | [3,662](/filings/0001630472-24-000028.md) | [3,731](/filings/0001630472-26-000004.md) | [3,962](/filings/0001630472-25-000013.md) | [4,162](/filings/0001630472-25-000022.md) | [4,065](/filings/0001630472-25-000030.md) | [4,406](/filings/0001630472-26-000030.md) | [4,472](/filings/0001630472-26-000017.md) | [4,597](/filings/0001630472-26-000026.md) | [5,243](/filings/0001630472-26-000030.md) |
| Total liabilities | $m | [3,090](/filings/0001630472-25-000005.md) | [2,708](/filings/0001630472-24-000012.md) | [2,572](/filings/0001630472-24-000025.md) | [2,537](/filings/0001630472-24-000028.md) | [2,617](/filings/0001630472-26-000004.md) | [2,858](/filings/0001630472-25-000013.md) | [3,071](/filings/0001630472-25-000022.md) | [2,982](/filings/0001630472-25-000030.md) | [3,338](/filings/0001630472-26-000030.md) | [3,410](/filings/0001630472-26-000017.md) | [3,552](/filings/0001630472-26-000026.md) | [4,219](/filings/0001630472-26-000030.md) |
| Long-term debt | $m | [3,048](/filings/0001630472-24-000006.md) | [2,664](/filings/0001630472-24-000012.md) | [2,528](/filings/0001630472-24-000025.md) | [2,493](/filings/0001630472-24-000028.md) | [2,572](/filings/0001630472-25-000005.md) | [2,826](/filings/0001630472-25-000013.md) | [3,037](/filings/0001630472-25-000022.md) | [2,947](/filings/0001630472-25-000030.md) | [3,309](/filings/0001630472-26-000004.md) | [3,382](/filings/0001630472-26-000017.md) | not reported | not reported |
| Shareholders' equity | $m | [1,125](/filings/0001630472-26-000004.md) | [1,121](/filings/0001630472-25-000030.md) | [1,124](/filings/0001630472-25-000030.md) | [1,125](/filings/0001630472-25-000030.md) | [1,114](/filings/0001630472-26-000030.md) | [1,104](/filings/0001630472-26-000030.md) | [1,091](/filings/0001630472-26-000030.md) | [1,083](/filings/0001630472-26-000030.md) | [1,068](/filings/0001630472-26-000030.md) | [1,062](/filings/0001630472-26-000030.md) | [1,044](/filings/0001630472-26-000030.md) | [1,024](/filings/0001630472-26-000030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [23.2 d](/filings/0001630472-26-000004.md) | [37.4](/filings/0001630472-25-000013.md) | [25.6 d](/filings/0001630472-25-000022.md) | [23.7 d](/filings/0001630472-25-000030.md) | [25.5 d](/filings/0001630472-26-000004.md) | [19.1](/filings/0001630472-26-000017.md) | [24.7 d](/filings/0001630472-26-000026.md) | [21.8 d](/filings/0001630472-26-000030.md) | [24.7 d](/filings/0001630472-26-000004.md) | [24.6](/filings/0001630472-26-000017.md) | [21.6 d](/filings/0001630472-26-000026.md) | [14.4 d](/filings/0001630472-26-000030.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001630472-26-000004.md) | [0.0](/filings/0001630472-25-000013.md) | [0.0 d](/filings/0001630472-25-000022.md) | [0.0 d](/filings/0001630472-25-000030.md) | [0.0 d](/filings/0001630472-26-000004.md) | [2.8](/filings/0001630472-26-000017.md) | [12.9 d](/filings/0001630472-26-000026.md) | [9.3 d](/filings/0001630472-26-000030.md) | [0.4 d](/filings/0001630472-26-000004.md) | [4.2](/filings/0001630472-26-000017.md) | [10.9 d](/filings/0001630472-26-000026.md) | [9.5 d](/filings/0001630472-26-000030.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.1](/filings/0001630472-24-000012.md) | [77.4](/filings/0001630472-24-000025.md) | [77.7](/filings/0001630472-24-000028.md) | [77.9](/filings/0001630472-25-000013.md) | [80.9](/filings/0001630472-25-000022.md) | [81.4](/filings/0001630472-25-000030.md) | [81.8](/filings/0001630472-26-000017.md) | [80.2](/filings/0001630472-26-000026.md) | [78.8](/filings/0001630472-26-000030.md) | [79.1](/filings/0001630472-26-000017.md) | [78.0](/filings/0001630472-26-000026.md) | [76.5](/filings/0001630472-26-000030.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 75,826,954 at 2026-10-23, from the cover of the [10-Q filed 2026-10-26](/filings/0001630472-26-000030.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 26, 2026, 16:26 ET. No prices; not investment advice.